Bullous pemphigoid is a chronic, relapsing skin disease with underlying type 2 inflammation. It is characterized by intense itching, blisters, skin reddening, and painful lesions. Dupilumab is ...

The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults ... by type 2 inflammation which causes blisters and rashes to form on the skin.

Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of painful and intensely itchy chronic lesions and blisters, in some cases ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating ...

and principal investigator of the study “People with bullous pemphigoid live with unrelenting itch, blisters, and painful lesions that can be debilitating and make it difficult to function daily.

Dupixent is a targeted medicine developed for treating bullous pemphigoid (BP), a chronic skin disease marked by intense itch and blisters. What significant results did the Dupixent trial achieve?

Bullous pemphigoid is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation and characterized by intense itch and blisters, reddening of the skin and painful lesions.

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

and principal investigator of the study “People with bullous pemphigoid live with unrelenting itch, blisters, and painful lesions that can be debilitating and make it difficult to function daily.

BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation and characterized by intense itch and blisters, reddening of the skin and painful lesions. “People with ...